GSK plc (NYSE:GSK) confirmed the sale of 385.3 million shares in Haleon plc (NYSE:HLN) for $1.58 billion. The shares represented around 4.2% of the issued share capital of Haleon. Following the settlement of the placing, GSK will have fully exited its position and will no longer hold any ordinary shares in Haleon.  See Also: Colgate-Palmolive Has Strong Brand-Building And Analytics-Driven Marketing Strategy, ...